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Abstract
Idiopathic pulmonary fibrosis (IPF) is a fatal disease of unknown cause that is char-
acterized by progressive fibrotic lung remodeling. An abnormal emergence of airway 
epithelial-like cells within the alveolar compartments of the lung, herein termed bron-
chiolization, is often observed in IPF. However, the origin of this dysfunctional distal 
lung epithelium remains unknown due to a lack of suitable human model systems. 
In this study, we established a human induced pluripotent stem cell (iPSC)-derived 
air-liquid interface (ALI) model of alveolar epithelial type II (ATII)-like cell dif-
ferentiation that allows us to investigate alveolar epithelial progenitor cell differen-
tiation in vitro. We treated this system with an IPF-relevant cocktail (IPF-RC) to 
mimic the pro-fibrotic cytokine milieu present in IPF lungs. Stimulation with IPF-RC 
during differentiation increases secretion of IPF biomarkers and RNA sequencing 
(RNA-seq) of these cultures reveals significant overlap with human IPF patient data. 
IPF-RC treatment further impairs ATII differentiation by driving a shift toward an 
airway epithelial-like expression signature, providing evidence that a pro-fibrotic cy-
tokine environment can influence the proximo-distal differentiation pattern of human 
lung epithelial cells. In conclusion, we show for the first time, the establishment of a 
human model system that recapitulates aspects of IPF-associated bronchiolization of 
the lung epithelium in vitro.
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1 |  INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is a lethal respiratory dis-
ease characterized by progressive fibrosis of the lung paren-
chyma and lung function decline,1 and despite the emergence 
of new therapies in nintedanib and pirfenidone that can slow 
down disease progression, the disease remains inevitably 
fatal.2 Evidence suggests that age-related and genetic predis-
position, as well as aberrant wound healing of lung epithe-
lial micro-injuries and dysregulated fibro-proliferative repair 
are involved in IPF pathogenesis.3,4 Dysfunctional epithelial 
repair in the IPF lung results in a loss of the normal proxi-
mo-distal patterning of the respiratory epithelium and an ab-
errant emergence of airway epithelial-like cell types within 
the alveolar regions of the lung, a phenomenon referred to 
as bronchiolization.5,6 Intermediate cells types, co-expressing 
alveolar, and conducting airway cell selective markers, reside 
in these bronchiolized regions, indicative of aberrant lung 
epithelial differentiation.7 Yet, the definite origin of the bron-
chiolized epithelial cells lining the microscopic honeycomb 
cysts of IPF patients remains unknown and the investigation 
of this complex process is complicated by a lack of suitable 
model systems.
The identification of specific bronchoalveolar cells as 
putative stem cells of the distal lung in mouse models of 
lung injury together with the observation of increased num-
bers of basal cell and club cell populations in IPF lesions 
have led to the hypothesis that the bronchiolized epithelium 
in IPF might originate from airway basal or bronchoalveo-
lar cell migration toward alveolar regions.8-11 However, the 
role of bronchoalveolar stem cells in human lung homeosta-
sis and repair remains debatable and several recent reports 
strongly suggest that a specified alveolar epithelial stem cell 
population, constituting a subpopulation of alveolar type II 
(ATII) cells residing within a specific mesenchymal niche, 
serves as the residual stem cell pool of the alveolar epithe-
lium.12-16 In line with this, it has been hypothesized that the 
susceptibility of surfactant secreting Alveolar type II cells 
(ATII cells) to injury and the resulting defective alveolar 
repair could play a major role in IPF disease onset and 
progression.15,17,18
Limited access to primary human ATII cells, particularly 
from diseased patients, and the rapid loss of ATII marker 
expression and function when cultured in vitro, make it 
challenging to study the role of human ATII cells in IPF.19 
Recent advances have led to the successful derivation of 
ATII-like cells from human pluripotent stem cells (hPSCs, 
including both embryonic stem cells and induced pluripotent 
stem cells (iPSCs)), providing a promising alternative cell 
source for in vitro disease modeling.20-26 Previous reports 
on hPSC-derived lung cells showed that despite their phe-
notypic similarities to mature lung epithelium, these models 
are equivalent to human fetal lung cells, rather than repre-
senting an adult state.27,28 We propose that hPSC-derived 
lung epithelial cultures constitute a highly valuable model 
to gain insights into the role of stem cells during lung repair 
and regeneration due to their immature nature by which they 
resemble adult alveolar epithelial progenitors (AEPs), a Wnt 
responsive subpopulation of ATII cells recently identified as 
the alveolar stem cell in the human lung that shows enrich-
ment of genes associated with lung development.16 This is 
in line with previous reports, highlighting the influence of 
developmental pathways in lung regeneration.29-31 Moreover, 
a role for aberrantly activated developmental pathways, in-
cluding Wnt, SHH, Notch, and FGF signaling, has also been 
described in the pathogenesis of IPF, the progression of 
which is commonly viewed as a vicious cycle of lung injury 
and repair.32-34
In this study, we sought to investigate if iPSC-derived 
alveolar epithelial progenitor cells exposed to a pro-fibrotic 
environment could recapitulate phenotypic and functional 
features of the aberrant epithelial remodeling in IPF cystic 
lesions and thereby serve as a human in vitro model of bron-
chiolization. Building on previous efforts to derive alveolar 
epithelium from hPSCs, we first aimed to develop a novel 
model system that allows human ATII-like differentiation 
from iPSCs in 2D air-liquid interface (ALI) culture to mimic 
the physiological environment of the lung epithelium. We 
next aimed to apply this model to studying alveolar epithelial 
dysfunction in IPF by exposing iPSC-derived alveolar epi-
thelial progenitor cells to an IPF-relevant cocktail (IPF-RC), 
based on upregulated cytokines found in IPF patient broncho-
alveolar lavage or sputum.35-43
2 |  MATERIALS AND METHODS
2.1 | Composition of an IPF-relevant 
cytokine cocktail (IPF-RC)
A novel IPF-RC was designed to model aspects of the IPF-
related lung milieu in vitro. A panel of nine cytokines, pre-
viously reported to be upregulated in clinical IPF BAL or 
sputum samples compared to healthy control lungs, was se-
lected based on a literature research. To approximately ac-
count for dilution in saline during sample collection, cytokine 
concentrations one order of magnitude higher than measured 
in IPF patient BAL were estimated as suitable for in vitro 
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experiments. Long-term stimulation of cells with IPF-RC 
was performed to simulate the cytokine milieu present in 
an IPF lung. The composition of IPF-RC is summarized in 
Table  1. All human recombinant cytokines were acquired 
from R&D Systems, Minneapolis, MN, US, and IPF-RC was 
prepared as a 1000× stock in 0.1% of BSA in PBS.
2.2 | IPF patient samples
Formalin-fixed and paraffin embedded lung samples from 
human IPF patients were purchased from Folio Biosciences 
(Powell, OH, US) under the regulatory conditions of the 
Boehringer Ingelheim corporate policy regarding the acquisi-
tion and use of human biospecimen. Samples were reviewed 
internally by a trained pathologist and the initial diagnosis of 
IPF was confirmed.
2.3 | Human iPSC culture
Human iPSC lines SFC065-03-03 (EBiSC: STBCi057-A, 
Biosamples ID: SAMEA104493762) and SFC084-03-01 
(EBiSC: STBCi033-A, Biosamples ID: SAMEA104493681) 
were obtained from the StemBANCC consortium. iPSCs were 
cultured in mTeSR 1 (Stemcell Technologies, Vancouver, 
Canada) on hESC-qualified matrigel (Corning, New York, 
US) coated cell culture plates at 37°C/5% CO2 in a humidi-
fied normoxic incubator.
2.4 | Differentiation of human iPSCs into 
ATII-like cells in 2D ALI culture
Directed differentiation of iPSCs toward NKX2.1+ lung 
progenitor cells was performed in serum-free differentiation 
medium, as previously described.44 On day 24 of differentia-
tion, lung progenitor cells were briefly digested with warm 
0.05% of Trypsin/0.53 mM of EDTA and detached as clumps 
and collected via sedimentation. The cells were plated onto 
hESC-qualified matrigel (Corning, New York, US) coated 
transwell permeable support inserts (PET membrane, 12 
well format, pore size 0.4 µm, Corning, New York, US) and 
cultured under submerged conditions until day 32 to allow 
the cells to attach and to spread out over the whole insert 
surface. Subsequently, the apical medium was removed and 
the cells were cultured at ALI until day 49 of differentiation. 
Similar to a previous study, temporal withdrawal of Wnt 
signaling was employed to promote distal lung epithelial 
progenitor differentiation toward ATII-like cells.23 From day 
24 to day 35 of differentiation, lung progenitors were cul-
tured in SFD+ medium supplemented with 3 µM CHIR99021 
T A B L E  1  Literature-based composition of an IPF-relevant cytokine cocktail (IPF-RC)
Cytokine Previous investigations of IPF BAL or sputum IPF-RC (ng/mL)
TGF-β1 32 pg/mL in IPF sputum (n = 15), undetectable in healthy sputum (n = 30)1 0.3
22.1 pg/mL in IPF with emphysema BAL (n = 38); 14.4 pg/mL in IPF without emphysema BAL (n = 64)2
1500 pg/mL in IPF BAL (n = 16)3
IL-1β 0.6 pg/mL in IPF BAL (n = 77), <0.3 pg/mL in healthy BAL (n = 349)4 0.01
2.4 pg/mL in IPF BAL (n = 11)5
TNF-α 1.9 pg/mL in IPF BAL (n = 11)5 0.1
10 pg/mL in IPF sputum (n = 15), 6.8 pg/mL in healthy sputum (n = 30)1
0.87 pg/mL in IPF with emphysema BAL (n = 38); 0.41 pg/mL in IPF without emphysema BAL (n = 64)2
IL-8 38.4 pg/mL in IPF BAL (n = 11)5 1.5
276 pg/mL in IPF sputum (n = 15), 46 pg/mL in healthy sputum (n = 30)1
35 pg/mL in IPF BAL (n = 13), 15 pg/mL in healthy BAL (n = 9)6
179 pg/mL in IPF with emphysema BAL (n = 38); 108 pg/mL in IPF without emphysema BAL (n = 64)2
44.6 pg/mL in IPF BAL (n = 7)7
MCP1 70 pg/mL in IPF BAL (n = 13), 5 pg/mL in healthy BAL (n = 9)6 0.7
555 pg/mL in IPF with emphysema BAL (n = 38); 351 pg/mL in IPF without emphysema BAL (n = 64)2
IL-33 4.13 pg/mL in IPF BAL (n = 100), 1.15 pg/mL in healthy BAL (n = 40)8 0.04
TSLP 2.5 pg/mL in IPF BAL (n = 11)5 0.1
9.27 pg/mL in IPF BAL (n = 100), 4.49 pg/mL in healthy BAL (n = 40)8
IL-13 250 pg/mL in IPF BAL (n = 16), 60 pg/mL in healthy BAL (n = 8)9 2.5
IL-4 16 pg/mL in IPF BAL (n = 16), 3 pg/mL in healthy BAL (n = 8)9 0.16
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(Axon Medchem, Groningen, Netherlands), 10  ng/mL of 
rhKGF (R&D Systems, Minneapolis, MN, US), 10 ng/mL of 
rhFGF10 (R&D Systems, Minneapolis, MN, US), 25 ng/mL 
of dexamethasone (Sigma-Aldrich, St. Louis, MO, US), 
0.1 mM of 8-Br-cAMP (Sigma-Aldrich, St. Louis, MO, US), 
and 0.1 mM of 3-Isobutyl-1-methylxanthine (Sigma-Aldrich, 
St. Louis, MO, US). Subsequently, the cells were treated with 
the same medium, but without CHIR99021, from day 35 to 
42, before 3 µM CHIR99021 was added back for one more 
week until day 49 of differentiation. The culture medium 
was exchanged every other day during the whole matura-
tion phase. Where indicated in the text, additional treatments 
were applied during differentiation from day 35 to day 49.
2.5 | Branching organoid formation of 
iPSC-derived lung epithelial progenitor cells
Branching of iPSC-derived lung epithelial progenitor cells 
was induced in 3D culture, similar to previous reports.27 
Cells were cultured in SFD+ medium supplemented 
with 3  µM CHIR99021 (Axon Medchem, Groningen, 
Netherlands), 10  ng/mL of rhKGF (R&D Systems, 
Minneapolis, MN, US), and 10 ng/mL of rhFGF10 (R&D 
Systems, Minneapolis, MN, US). On day 24 of differen-
tiation, lung progenitor cells were briefly digested with 
warm 0.05% of Trypsin/0.53 mM of EDTA and detached 
as clumps, which were collected at the bottom of a canoni-
cal tube via sedimentation and plated onto low attachment 
dishes. The following day, the resulting organoids were em-
bedded into cold growth factor reduced matrigel (Corning, 
New York, US) on 48-well tissue culture plates. Following 
solidification of the matrigel, the organoids were covered 
with medium and cultured for up to 35 days. The medium 
was changed every 2 days.
2.6 | ATI-like differentiation of  
iPSC-derived ATII-like cells
ATI-like differentiation of iPSC-derived ATII cells was 
induced by replating cells on plastic in 2D submerged cul-
ture, as previously described.23 On day 49 of differentia-
tion ATII-like cells were dissociated using Gibco StemPro 
Accutase cell dissociation reagent (Life Technologies. 
Carlsbad, CA, US) and replated onto 6-well tissue culture 
plates in Gibco DMEM Glutamax (Life Technologies. 
Carlsbad, CA, US) supplemented with 10% of FBS (Life 
Technologies. Carlsbad, CA, US). Media was changed 
every other day and cells were harvested for analysis after 
5  days. Controls were not replated and remained at ALI 
on transwell permeable support inserts until they were har-
vested on day 54 of differentiation.
2.7 | Primary human small airway epithelial 
cell culture
Primary human Small Airway Epithelial Cells (SAECs) 
(CC-2547, Lot 501937, Lonza, Basel, Switzerland) were 
thawed into a T-175 tissue culture flask and expanded 
for 4  days in PneumaCult-Ex Plus Medium (Stemcell 
Technologies, Vancouver, Canada). A single cell suspen-
sion was then created using an Animal Component-Free 
Cell Dissociation Kit (Stemcell Technologies, Vancouver, 
Canada) and 90 000 cells/cm2 were seeded onto rat tail col-
lagen type I (Corning, New York, US) coated transwell per-
meable support inserts (PET membrane, 24 well format, pore 
size 0.4 µm, Corning, New York, US). Four days post seed-
ing, the apical medium was removed and the cells were dif-
ferentiated at ALI in PneumaCult-ALI-S medium (Stemcell 
Technologies, Vancouver, Canada) for 28 days. The culture 
medium was exchanged every other day. Where indicated 
in the text, IPF-RC treatment was applied to SAEC cultures 
from 1 to 28 days post-ALI.
2.8 | Primary human lung fibroblast culture
Primary human lung fibroblasts (CC-2512, Lot. 0000608197, 
Lonza, Basel, Switzerland) were grown in fibroblast basal 
medium (FBM) (Lonza, Basel, Switzerland) supplemented 
with FGM-2 SingleQuot Kit Supplements & Growth Factors 
(Lonza, Basel, Switzerland) at 37°C and 5% CO2. Cells were 
passaged maximum 10 times before use.
2.9 | Quantitative Real-Time PCR
RNA isolation was performed using the RNeasy Plus Mini 
Kit (Qiagen, Venlo, Netherlands). In some experiments, 
human lung total RNA (AM7968, Lot.1850512, Invitrogen, 
Life Technologies, Carlsbad, CA, US) was used as a posi-
tive control. Reverse transcription was performed using 
the Applied Biosystems High-Capacity cDNA Reverse 
Transcription Kit (Life Technologies, Carlsbad, CA, US). 
About 5 ng of cDNA were added to a final reaction volume 
of 10 µL containing the QuantiFast Probe PCR +ROX Vial 
Kit (Qiagen, Venlo, Netherlands) master mix and the respec-
tive Applied Biosystems TaqMan Gene Expression Assay 
FAM (Life Technologies, Carlsbad, CA, US). qPCR was 
performed using an Applied Biosystems ABI ViiA 7 real-
time PCR System (Life Technologies, Carlsbad, CA, US). 
Gene expression was normalized to GAPDH control and fold 
change in gene expression relative to iPSCs (day 0 of differ-
entiation) was calculated using the 2^(−ΔΔCT) method. A 
list of all TaqMan Gene Expression Assays used in this study 
is provided in Table 2.
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2.10 | RNA extraction, Illumina library 
preparation, and RNA sequencing (RNA-seq)
Total RNA of iPSC-derived day 0, day 24, and day 49 cul-
tures (three biological replicates per timepoint) was extracted 
using the Ambion MagMax-96 total RNA isolation kit (Life 
Technologies, Carlsbad, CA, US). Nucleic acids were cap-
tured onto magnetic beads, treated with DNase, and total 
RNA was eluted Concentration were measured using an RNA 
Pico chip on a Bioanalyzer (Agilent, Santa Clara, CA, US).
A sequencing library was prepared using the TrueSeq 
RNA Sample Prep Kit v2-Set B (Illumina, San Diego, CA, 
US) with 200  ng of total RNA input per sample, resulting 
in an average fragment size of 275  bp including adapters. 
Before sequencing, eight individual libraries were normal-
ized and pooled together using the adapter indices supplied 
by the manufacturer. Pooled libraries were then clustered on 
an Illumina cBot Instrument using the TruSeq SR Cluster Kit 
v3—cBot—HS (Illumina, San Diego, CA, US). Sequencing 
was performed as 50 bp, single reads and 7 bases index read 
on an Illumina HiSeq2000 instrument using the TruSeq SBS 
Kit HS- v3 (50-cycle) (Illumina, San Diego, CA, US).
2.11 | Bioinformatic analysis of  
RNA-seq data
2.11.1 | Step-by-step RNA-seq pipeline
A step-by-step bioinformatics pipeline was utilized to pro-
cess and technically validate the RNA-seq data. The pipeline 
was described in detail in a previous study.45
2.11.2 | Detection of differentially 
expressed genes
Comparative analysis was done using the limma R-package.46 
Benjamini-Hochberg correction was used to adjust for mul-
tiple testing.
2.11.3 | Heatmaps
A heatmap of the top 500 genes deregulated in iPSC-de-
rived day 49 cultures vs day 24 cultures was created uti-
lizing the heatmap3 package of R statistical software and 
the following cutoff values: q-val  <  0.001, |logFC|  >  2, 
maxRPKM > 10.
2.11.4 | Principle component analysis (PCA)
PCA was performed as previously described, using 
ClustVis.47 The top 5000 transcripts according to the coef-
ficient of variation were selected for analysis.
2.11.5 | Gene set enrichment analysis 
(GSEA)
Normalized expression data for day 49 +IPF-RC and day 
49 samples were analyzed using the GSEA method.48 Genes 
were ranked by magnitude of correlation with a class distinc-
tion, and the GSEA algorithm determined whether members 
of a gene set tended to occur toward the top or bottom of 
the list, and calculated an enrichment score. In order to re-
move extremely low or not at all expressed transcripts from 
the data set, NGS data were filtered according to an RPKM 
T A B L E  2  List of TaqMan Gene Expression Assays used in this 
study
Target Assay ID Vendor
ABCA3 Hs00184543_m1 Applied Biosystems
ACTA2 Hs00426835_g1 Applied Biosystems
AGER/RAGE Hs00542584_g1 Applied Biosystems
AQP5 Hs00387048_m1 Applied Biosystems
BPIFB1 Hs00264197_m1 Applied Biosystems
CAV1 Hs00971716_m1 Applied Biosystems
CDH1 Hs01023895_m1 Applied Biosystems
COL1A1 Hs00164004_m1 Applied Biosystems
FOXA2 Hs00232764_m1 Applied Biosystems
FOXJ1 Hs00230964_m1 Applied Biosystems
GAPDH Hs02758991_g1 Applied Biosystems
ID2 Hs04187239_m1 Applied Biosystems
KRT5 Hs00361185_m1 Applied Biosystems
MMP10 Hs00233987_m1 Applied Biosystems
MMP7 Hs01042796_m1 Applied Biosystems
MUC5AC Hs01365616_m1 Applied Biosystems
MUC5B Hs00861595_m1 Applied Biosystems
NKX2.1/TTF1 Hs00968940_m1 Applied Biosystems
PDPN Hs00366766_m1 Applied Biosystems
POU5F1 Hs00999632_g1 Applied Biosystems
SCGB1A1 Hs00171092_m1 Applied Biosystems
SFTPB Hs00167036_m1 Applied Biosystems
SFTPC Hs00161628_m1 Applied Biosystems
SOX17 Hs00751752_s1 Applied Biosystems
SOX2 Hs01053049_s1 Applied Biosystems
SOX9 Hs00165814_m1 Applied Biosystems
TM4SF1 Hs01547334_m1 Applied Biosystems
TP63 Hs00978340_m1 Applied Biosystems
6 |   SCHRUF et al.
value > 2 in at least one of the samples. Gene sets that were 
significantly associated with the day 49 +IPF-RC class were 
identified from the C2.CP.REACTOME (Curated) collec-
tion of gene sets in the Molecular Signatures Database v6.2 
(MSigDB), which comprises 674 gene sets.49 The null dis-
tributions used to calculate the statistical significance of the 
enrichment scores were generated by permutation of gene 
sets for the day 49 +IPF-RC vs day 49 contrast (3 replicates/
class). Adjustment for multiple hypothesis testing was per-
formed by determination of FDR. Enrichment scores with an 
FDR q-value < 0.05 were considered to be significant.
2.11.6 | Calculation of intersections with 
IPF lung RNA-seq data set
Expression data for day 49 +IPF-RC and day 49 samples 
were compared to publicly available data for human IPF and 
healthy lung tissue.50 Transcripts used for calculating the 
intersections were selected according to being expressed (at 
least one sample showing an RPKM > 2) in both data sets. 
This resulted in a universe of 12 365 transcripts. Deregulated 
transcripts were defined by exhibiting a q-value < 0.05 and 
an absolute log ratio of >0.5. Resulting gene sets were split 
into upregulated and downregulated and the intersection of 
the corresponding gene sets from both data sets was calcu-
lated. Significance of the intersection was tested via a hyper-
geometric test.
2.11.7 | ChIP Enrichment Analysis 
(ChEA) of RNA-seq data
Transcription factor enrichment analysis was performed on 
a pre-ranked gene list according to log2 fold change (adj. P-
val < .05, a total of 1057 gene sets) and compared with the 
Literature ChIP-seq library using the web-based tool (https://
amp.pharm.mssm.edu/ChEA3) available from Ma'ayan 
Laboratory.51
2.12 | Measurement of total cell number and 
Caspase-3/7 activity
The total cell number per insert of iPSC-derived day 49 
cultures was assessed by dissociating the cultures with 
Gibco StemPro Accutase cell dissociation reagent (Life 
Technologies, Carlsbad, CA, US) and counting of cells with 
a TC20 Automated Cell Counter (Bio-Rad, Hercules, CA, 
US). Caspase-3/7 activity of day 49 cultures was measured 
using a Caspase-Glo 3/7 Assay Kit (Promega, Madison, WI, 
US).
2.13 | Measurement of MMP protein 
concentrations by ELISA
Matrix metalloproteinase (MMP)-7 and MMP-10 protein 
concentrations in cell culture supernatants were determined 
using a Human Total MMP-7 DuoSet ELISA (R&D Systems, 
Minneapolis, MN, US) and a Human Total MMP-10 DuoSet 
ELISA (R&D Systems, Minneapolis, MN, US).
2.14 | Flow cytometry
Flow cytometry was performed on day 24 of differentiation. 
Lung progenitors were dissociated and taken up into ice 
cold 1% of BSA in PBS. All washing steps were performed 
by applying ice cold wash buffer (0.1% BSA in PBS) and 
pelleting at 300g for 5 minutes. 1 × 106 cells were trans-
ferred into a FACS tube and washed, before prewarmed 
Cytofix fixation buffer (BD Biosciences, Franklin Lakes, 
NJ, US) was added (10 minutes at 37°C). Cells were then 
washed and permeabilized in 80% of MeOH for 5 minutes, 
followed by 0.1% of Tween-20 (Sigma-Aldrich, St. Louis, 
MO, US) for 10 minutes. Blocking was performed in 10% 
of goat serum (Sigma-Aldrich, St. Louis, MO, US) for 
10 minutes. Cells were washed and incubated in the respec-
tive Alexa Fluor conjugated antibody for 30 minutes in the 
dark. Isotype controls were incubated in 1 µg/mL of Alexa 
Fluor 488 conjugated rabbit IgG Isotype Control (Abcam, 
Cambridge, UK) and samples for NKX2.1 staining were 
incubated in 1  µg/mL of Alexa Fluor conjugated anti-
TTF1 antibody (Abcam, Cambridge UK). The cells were 
then washed, resuspended in Cellfix (BD Biosciences) and 
transferred through a 35  µm strainer cap. Samples were 
measured on a LSR II flow cytometer (BD Biosciences, 
Franklin Lakes, NJ, US) and analyzed using the FACSDiva 
(BD Biosciences, Franklin Lakes, NJ, US) and the FloJo 
(FlowJo LLC) software.
2.15 | Immunohistochemistry
All primary and secondary antibodies used in this study are 
listed in Table 3.
2.15.1 | Hematoxylin and eosin and Alcian 
Blue/PAS stainings
Transwell cultures were fixed for 30  minutes with 4% of 
Paraformaldehyde (BosterBio, Pleasanton, CA, US) at room 
temperature and the whole membrane was cut out of the in-
sert for further processing. Fixed inserts were dehydrated 
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and embedded into paraffin following standard procedures. 
Transwell insert cross-sections or sections of paraffin-
embedded IPF lung samples of 3  µm thickness were pre-
pared and rehydrated using a descending series of ethanol. 
Hematoxylin and eosin (H&E) and Alcian Blue/PAS stain-
ings were performed according to standard protocols. Images 
were acquired with an AxioCam MR3 (Zeiss, Oberkochen, 
Germany) using the 20× objective of an Axio Imager Z1 
(Zeiss, Oberkochen, Germany).
2.15.2 | Immunofluorescence of iPSC-
derived and primary cells
For immunofluorescence of lung epithelial progenitor cells, 
VAFE cell clumps were replated and expanded on hESC-
qualified matrigel (Corning, New York, US) coated glass bot-
tom plates (12-well, No. 1.5 coverslip, 14 mm glass diameter, 
MatTek, Ashland, MA, US). On day 24 of differentiation, 
cells were fixed for 15 minutes with 4% of Paraformaldehyde 
(BosterBio, Pleasanton, CA, US) at room temperature. The 
fixed samples were washed with PBS and blocked for 1 hour 
at room temperature in 5% of BSA with 0.3% of TritonX-100 
(Sigma-Aldrich, St. Louis, MO, US) in PBS. The cells were 
then incubated with the respective primary and secondary 
antibodies according to standard protocols. To visualize the 
nuclei, the cells were stained with 2 µg/mL of Hoechst 33342 
(Life Technologies, Carlsbad, CA, US) for 5 minutes.
For immunofluorescence of transwell inserts, iPSC- 
derived ATII-like cells or primary SAEC cultures were fixed 
for 30  minutes with 4% of Paraformaldehyde (BosterBio, 
Pleasanton, CA, US) at room temperature. The inserts were 
then washed with PBS and the whole membrane was cut out 
of the insert for further processing.
Whole insert stainings were performed after blocking the 
fixed cells on the membrane for 1 hour at room temperature 
in 5% of BSA with 0.3% of TritonX-100 (Sigma-Aldrich, 
St. Louis, MO, US) in PBS, by incubating them in the respec-
tive primary and secondary antibodies according to standard 
protocols. The membranes were then washed in PBS, mounted 
with Invitrogen ProLong Diamond Antifade Mountant with 
DAPI (Life Technologies, Carlsbad, CA, US) and coverslipped.
For staining of insert cross-sections and definitive endo-
derm bodies, fixed specimen were dehydrated using a Tissue 
Tek VIP processor and embedded into paraffin blocks. 
Sections of 3  µm thickness were prepared, deparaffinized 
with xylene, and rehydrated using a descending series of eth-
anol. Antigen retrieval was performed for 30 minutes at 95°C 
in HIER sodium citrate solution (BioLegend, San Diego, CA, 
US). The samples were blocked for 1 hour at room tempera-
ture with 5% of normal goat or normal donkey serum (Sigma-
Aldrich, St. Louis, MO, US) in PBS and incubated with the 
respective primary and secondary antibodies according to 
standard protocols. The sections were then mounted with 
Invitrogen ProLong Diamond Antifade Mountant with DAPI 
(Life Technologies, Carlsbad, CA, US) and coverslipped.
All specimens were imaged with a LSM 710 confocal 
microscope system (Zeiss, Oberkochen, Germany) with an 
T A B L E  3  List of antibodies used in this study
Antibody Cat. No. Vendor
ABCA3 (rabbit polyclonal) ab99856 abcam
Collagen type I (mouse IgG1) SAB4200678 Sigma-Aldrich
E-Cadherin (rabbit IgG) 3195S Cell Signaling
FOXA2 (goat IgG) AF2400 R&D systems
KRT5 (guinea pig polyclonal) GP-CK5 Progen
MUC5AC (mouse IgG1k) MA1-38223 Invitrogen
MUC5B (rabbit polyclonal) HPA008246 Sigma-Aldrich
NKX2.1/TTF1 (mouse IgG1k) MA5-13961 Invitrogen
NKX2.1/TTF1 (rabbit IgG) WRAB-1231 Seven Hills
Pro-SFTPC (rabbit polyclonal) AB3786 Millipore
SFTPB (rabbit polyclonal) WRAB-48604 Seven Hills
SFTPC (rabbit IgG) HPA010928 Sigma-Aldrich
SOX9 (rabbit IgG) HPA001758 Sigma-Aldrich
Vimentin (rabbit IgG) ab92547 abcam
KRT5 (rabbit IgG) Alexa Fluor 
647 conjugated
ab193895 abcam
NKX2.1/TTF1 (rabbit IgG) 
Alexa Fluor 488 conjugated
ab196470 abcam
Donkey anti goat IgG Alexa 
Fluor 488 conjugated
A-11055 Invitrogen
Donkey anti rabbit IgG Alexa 
Fluor 594 conjugated
A-21207 Invitrogen
Donkey anti rat IgG Alexa 
Fluor 488 conjugated
A-21208 Invitrogen
Goat anti guinea pig IgG Alexa 
Fluor 568 conjugated
A-11075 Invitrogen
Goat anti mouse IgG Alexa 
Fluor 488 conjugated
A-11029 Invitrogen
Goat anti mouse IgG1 Alexa 
Fluor 568 conjugated
A-21124 Invitrogen
Goat anti mouse IgG Alexa 
Fluor 594 conjugated
A-11032 Invitrogen
Goat anti rabbit IgG Alexa 
Fluor 488 conjugated
A-11034 Invitrogen
Goat anti rabbit IgG Alexa 
Fluor 568 conjugated
A-11011 Invitrogen
Goat anti rabbit IgG Alexa 
Fluor 647 conjugated
A-21245 Invitrogen
Goat anti rat IgG Alexa Fluor 
594 conjugated
A-11007 Invitrogen
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AXIO Observer Z1 using a Plan-Apochromat 20× objective 
or a Plan-Apochromat 40× water-immersion objective.
2.15.3 | Immunohistochemistry of IPF 
lung sections
Immunohistochemistry in IPF patient samples was carried 
out on the automated Leica IHC Bond-RX platform (Leica 
Biosystems, Nussloch, Germany) using the Opal method 
(Perkin Elmer, Waltham, MA, US). Three µm thick sections 
of FFPE IPF lung tissue on super frost plus slides were depar-
affinized and rehydrated for multiplex immunohistochemistry 
staining. Antigen retrieval was performed for all primary an-
tibodies by heating the sections in Bond ER solution 1 buffer 
(Leica Biosystems, Nussloch, Germany) at 95°C; pH 6.0 
for 20 minutes. Primary antibodies were diluted with Leica 
Primary Antibody Diluent (Leica Biosystems, Nussloch, 
Germany) and sections were incubated with them for 30 min-
utes at room temperature followed by incubation (10 minutes at 
RT) with Opal Polymer Anti-Rabbit HRP Kit (ARR1001KT; 
Perkin Elmer Waltham, MA, US). Immunofluorescent sig-
nal was visualized using the OPAL (Perkin Elmer, Waltham, 
MA, US) TSA dye 570 and TSA dye 650 and counterstained 
with Spectral DAPI (Akoya, Menlo Park, CA). Microscopy 
of IPF lung samples was conducted with an AxioImager M2 
microscope (Zeiss, Oberkochen, Germany) and images were 
created using an AxioScan scanner and ZEN slidescan soft-
ware (Zeiss, Oberkochen, Germany).
2.16 | Semi-quantitative measurement of 
SFTPC+ area in iPSC-derived cultures
Immunofluorescence of fixed whole transwell inserts was 
performed as described above. All samples of an experiment 
were stained and imaged on the same day. Nine randomly 
selected areas per insert (425.1  µm  ×  425.1  µm per area) 
were captured using a 20× Plan-Apochromat objective on a 
LSM 710 confocal microscope system (Zeiss, Oberkochen, 
Germany) with the following settings: Alexa Fluor 488 chan-
nel, 5% of laser power, master gain 600, acquisition speed 
9, resolution 1024 px × 1024 px. To account for unevenness 
in specimen surface and thickness, Z-stack imaging of 20 
vertical stacks per area was applied and maximum intensity 
projection was performed using the ZEN 2012 Black Edition 
software (Zeiss, Oberkochen, Germany). Image analysis was 
then performed using the Fiji for ImageJ software.52 Each 
image was first converted to 8-bit format, and then, converted 
to binary at a threshold of 20-255. In the following, parti-
cles within areas >80 px were analyzed and summarized per 
image. For each analyzed transwell insert, the mean positive 
area per image was calculated from the nine selected areas.
2.17 | Visual collagen I quantification in 
primary human lung fibroblast cultures
Primary human lung fibroblasts were plated in a poly-
D-lysine coated 384 CellCarrier microtiter plate from 
PerkinElmer in FBM with FGM-2TM Single Quots 
(Lonza, Basel, Switzerland) at a density of 1000 cells 
per well. After 24 hours, the medium was replaced by the 
same medium containing no serum (starvation medium). 
Forty-eight hours cell seeding, the starvation medium was 
replaced with starvation medium containing a mixture 
of Ficoll 70 and 400 (GE Healthcare, Chicago, IL, US; 
37.5 mg/mL and 25 mg/mL, respectively), 200 µM of vi-
tamin C, and IPF-RC (1:1000 dilution). After 72  hours, 
the cell culture medium was removed and cells were fixed 
with 100% of ice-cold methanol for 30  minutes. Next, 
cells were washed with PBS, permeabilized for 20 minutes 
using 1% of Triton-X-100 (Sigma-Aldrich, St. Louis, MO, 
US), washed and blocked for 30 minutes with 3% of BSA 
in PBS. After an additional wash step, cell nuclei were 
stained with 1 µM of Hoechst 33342 (Life Technologies. 
Carlsbad, CA, US) and collagen I was stained using a 
monoclonal antibody (SAB4200678, Sigma-Aldrich, St. 
Louis, MO, US). For primary antibody detection, cells 
were washed and incubated for 30  minutes at 37°C with 
Goat anti mouse IgG1 Alexa Fluor 568 secondary anti-
body. After secondary antibody removal, cells were stained 
with Invitrogen HCS Cell Mask Green stain (1:50 000, Life 
Technologies. Carlsbad, CA, US). Following a final wash 
step, images were acquired in an InCell 2200 Analyzer (GE 
Healthcare, Chicago, IL, US), using 2D-Deconvolution for 
nuclei (Hoechst channel), cells (FITC channel), and colla-
gen I (TexasRed channel), and images were transferred to 
the Columbus Image Storage and Analysis system (Perkin 
Elmer, Waltham, MA, US).
Image analysis was performed as previously described.53,54 
Briefly, using the building blocks of Perkin Elmer´s 
Columbus Image Analysis system, first nuclei acquired with 
the Hoechst channel were detected using the building block 
(BB) “nuclei.” Second, cells were defined with the BB “find 
cytoplasm” from the FITC channel. Collagen I area was 
defined by two individual BBs “find simple image region” 
based on images acquired in the TexasRed channel. Collagen 
I readouts were normalized to the number of cells per image 
field. Total number of cells, and total collagen area/total 
number of cells were used as parameters to quantify effects 
of IPF-RC.
2.18 | Transmission electron microscopy
For electron microscopy of iPSC-derived ATII-like cells, 
transwell inserts were prefixed for 1  hour with 4% of 
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Paraformaldehyde. The PET membrane with prefixed cells 
was then washed with a 0,1% of cacodylate buffer solution 
for 30 minutes. Afterward, the samples were transferred into 
an EM-TP Tissue processor (Leica Microsystems, Wetzlar, 
Germany) for automated postfixation, staining, dehydration, 
and embedding. In detail, the samples underwent the follow-
ing steps: 20 minutes in 0,1% of cacodylate buffer, 3 hours in 
1% of Daltons osmium tetroxide aq., three times 15 minutes 
in 0,1% of cacodylate buffer solution, 15 minutes in 30% of 
isopropanol, 30 minutes each in 30%, 50%, 70%, 90%, and 
100% isopropanol, and three times 1 hour in 100% of isopro-
panol. Following dehydration, sample infiltration with Epoxy 
resin was achieved as follows: 30 minutes in 50% of isopro-
panol/50% EPON, 30  minutes in 33% of isopropanol/66% 
EPON, 30 minutes in 20% of isopropanol/80% EPON, and 
60 minutes in 100% of EPON. The samples were then incu-
bated twice for 6 hours in 100% of EPON and hardened at 
60°C for 24 hours. Ultrathin sections (50 nm) were prepared 
on an Ultracut UCT ultra-microtome (Leica Microsystems, 
Wetzlar, Germany) and imaged on a TEM 912AB (Zeiss, 
Oberkochen, Germany).
2.19 | LysoTracker Green DND-26 live 
cell staining
iPSC-derived ATII-like cells were replated onto Nunc 8-well 
Lab-Tek Chambered Coverglasses (Thermo Fisher Scientific, 
Waltham, MA, US) and were allowed to attach overnight, be-
fore 100 nM LysoTracker Green DND-26 (Invitrogen, Life 
Technologies, Carlsbad, CA, US) was added into the medium 
and the cells were incubated for 20 minutes at 37°C protected 
from light. The medium was then removed and the sam-
ples were washed once with prewarmed Gibco FluoroBrite 
DMEM (Life Technologies, Carlsbad, CA, US), followed by 
a 5 minutes incubation in 5 ng/mL of Hoechst 33342 (Life 
Technologies, Carlsbad, CA, US) in FluoroBrite. Subsequent 
to three additional washes with FluoroBrite DMEM, fresh 
FluoroBrite DMEM was added to the cells and the samples 
were immediately imaged using a Plan-Apochromat 63× oil-
immersion objective on an LSM 710 confocal microscope 
system (Zeiss, Oberkochen, Germany).
2.20 | Cilia beat measurements in primary 
small airway cultures
Cilia beat frequency was calculated from image stacks of 
2D+time. Six evenly distributed regions of a transwell in-
sert were imaged using the 32× objective of an Axiovert 25 
microscope (Zeiss, Oberkochen, Germany) and an acA 1300-
200 µm black and white USB-3.0 high speed camera (Basler, 
Ahrensburg, Germany). Ciliary movement was recorded at 
100 frames per second for a total of 6  seconds per region. 
Applications for image capture and analysis were developed 
using the HALCON 13.0.2 machine vision software tool-
box (MVTec Software, Munich, Germany). Visualization of 
image stack was performed with Analyze (AnalyzeDirect, 
Overland Park, KS, US). A grey value time course was cal-
culated for each pixel over 512 frames per region. The area 
covered by motile cilia was determined by quantifying the 
percentage of pixels with a measurable beating frequency 
within a region. The mean ciliary beating frequency of a re-
gion was determined by calculating the average frequency of 
the change in grey values.
2.21 | Transepithelial electrical resistance 
(TEER) measurements
Transwell cultures were washed with pre-warmed PBS, 
before transepithelial electrical resistance (TEER) was 
measured using a STX-2 chopstick electrode attached to 
an EVOM2 Epithelial Volt/Ohm Meter (World Precision 
Instruments, Sarasota, FL, USA). The raw values were multi-
plied with the area of the transwell insert membrane to obtain 
the final TEER values in Ω*cm2.
2.22 | FITC-Dextran permeability assay
For dextran flux measurements in day 28 SAEC ALI cul-
tures, the medium in the basolateral compartment of the tran-
swell cultures was substituted with RPMI w/o phenol red 
(Gibco, Waltham, MA, USA). About 5  mg/mL of 10  kDa 
FITC-Dextran (Sigma-Aldrich, St. Louis, MO) in RPMI w/o 
phenol red was then added to the apical compartment of the 
insert and the cells were incubated at 37°C 5% CO2. About 
10 μL-samples were taken from the basolateral compartment 
after 0, 30, 60, and 90 minutes and the relative fluorescence 
intensity (excitation 490 nm, emission 520 nm) was meas-
ured using a SpectraMax M5 (Molecular Devices, San Jose, 
CA, USA).
2.23 | Primary human small airway basal 
cell proliferation assay
Primary human small airway basal cells (Lonza, Basel, 
Switzerland) were thawed and expanded for 4  days in 
PneumaCult-Ex Plus Medium (Stemcell Technologies, 
Vancouver, Canada), before 3 × 103 cells/well were seeded 
onto 96-well tissue culture plates. Twenty-four hours after 
seeding, the cells were stimulated with IPF-RC or 0.0001% 
of BSA in PneumaCult-Ex Plus Medium. Cell prolifera-
tion was determined after 0, 24, 48, and 72 hours using the 
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CyQUANT Direct Cell Proliferation Assay Kit (Invitrogen, 
Life Technologies, Carlsbad, CA, US) according to the man-
ufacturer's instructions.
2.24 | Statistical analysis
All qRT-PCR, ELISA, flow cytometry, and image analysis 
data are presented as mean with error bars representing the 
SD of at least three independent experiments. Experiments 
comparing two conditions only were analyzed using two-
tailed unpaired Student's t test, when variances were homo-
geneously distributed, or Mann-Whitney U-test, when data 
were not normally distributed. Experiments containing three 
or more conditions were assessed by two-way ANOVA, fol-
lowed by the Tukey test. Data analysis was performed using 
GraphPad Prism 8.0 (GraphPad Software). Significance val-
ues are marked as *P <  .05, **P <  .01, ***P <  .001 and 
****P < .0001.
3 |  RESULTS
3.1 | Differentiation of human iPSCs toward 
ATII-like cells in ALI culture
We established a directed step-wise differentiation protocol 
to derive ATII-like cells from human iPSCs, in which distal 
lung progenitor maturation toward ATII-like cells was car-
ried out on transwell inserts at ALI to mimic the physiological 
environment of the mature alveolar epithelium (Figure 1A). 
Adapting a previously published protocol,20,44 we generated 
NKX2.1+/FOXA2+/SOX9+ lung epithelial progenitor cells, 
via SOX17+ definitive endoderm and ventralized anterior 
foregut endoderm (Figures 1B-D and S1A,B). 3D matrigel 
culture was utilized to confirm the budding and branching 
potential of the iPSC-derived lung epithelial progenitor cells, 
which constitutes a key functional feature of fetal epithe-
lial progenitors during lung morphogenesis (Figure  S1C). 
Subsequently, to induce ATII-like differentiation, day 24 
lung epithelial progenitor cells were seeded onto transwell 
inserts and confluent cultures were further differentiated at 
air-liquid-interface until day 49, with temporal modulation 
of Wnt signaling applied to drive further differentiation of 
NKX2.1+ lung progenitor cells toward ATII-like cells.23 
SFTPC, Surfactant Protein B (SFTPB), and ABCA3 expres-
sion was induced over time (Figure  1E), together with an 
upregulation of many other ATII associated transcripts by 
day 49 (Figure 1F). Cells differentiated at air-liquid-interface 
displayed upregulated expression levels of SFTPC, SFTPB, 
and ABCA3 compared to submerged conditions, while no in-
duction of the ATI markers CAV1 or PDPN was observed 
under either condition (Figure  2A). Immunofluorescence 
showed the homogeneous expression of the pan-epithelial 
marker E-Cadherin and confirmed the presence of SFTPC+, 
SFTPB+, and ABCA3+ cells, indicative of an ATII cell phe-
notype (Figure 2B). Day 49 cultures also showed upregulated 
expression of the human alveolar epithelial progenitor marker 
TM4SF1 compared to iPSCs. Moreover, a moderate induc-
tion of basal cell markers (KRT5, TP63) and other airway 
related transcripts (SCGB1A1, MUC5B, and FOXJ1) was ob-
served and rare individual KRT5+ cells could be detected, 
indicating that in addition to ATII-like cells, our model sys-
tem contains airway basal-like cells (Figure S2A,B). Staining 
of cross-sectioned day 49 transwell cultures revealed that 
SFTPC+ cells resided mainly on the apical air-exposed sur-
face of the cultures (Figure 2C). ATII-specific lamellar body-
like structures were observed (Figure  2D) and live-stained 
iPSC-derived ATII-like cells contained large organelles 
displaying intensive accumulation of LysoTracker Green 
DND-26 (Figure 2E). Single cell dissociation and replating 
of iPSC-derived ATII-like cells under 2D submerged condi-
tions in serum-containing medium resulted in downregulated 
SFTPC, SFTPB, and ABCA3 expression and upregulated 
expression of the ATI markers CAV1 and PDPN, consist-
ent with ATI-like differentiation potential (Figure S2C). No 
vimentin+ cells were detected in day 49 cultures by immu-
nofluorescence, suggesting that mesenchymal cells were ab-
sent in the iPSC-derived ALI model (Figure S2D). Our ATII 
differentiation protocol was reproducible in an alternative 
human iPSC line (Figure S3).
3.2 | iPSC-derived distal lung epithelial 
progenitor differentiation in the presence of 
an IPF-relevant cytokine cocktail (IPF-RC) 
results in IPF-related changes in expression 
signature and secretory state
We utilized our iPSC-derived model system to investigate 
the effects of a pro-fibrotic environment on ATII cell dif-
ferentiation. An IPF-relevant cytokine cocktail (IPF-RC) 
was designed and was capable of inducing collagen I for-
mation in primary human lung fibroblasts (Figure S4). The 
IPF-RC, contains nine cytokines previously shown to be up-
regulated in IPF bronchoalveolar lavage or sputum samples 
compared to healthy controls (Transforming growth factor 
beta 1 (TGF-β1), Interleukin 1 beta (IL-1β), Tumor necrosis 
factor alpha (TNF-α), Interleukin 8 (IL-8), Monocyte chem-
otactic protein 1 (MCP1), Interleukin 33 (IL-33), Thymic 
stromal lymphopoietin (TSLP), Interleukin 13 (IL-13), and 
Interleukin 4 (IL-4); Table 1). IPF-RC was applied to iPSC-
derived alveolar epithelial progenitor cells for 2  weeks, 
 following the induction of SFTPC expression (Figures  1E 
and 3A). No changes in total cell number or caspase-3/7 ac-
tivity were detected upon IPF-RC treatment, indicating that 
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IPF-RC did not exert any anti-proliferative or pro-apoptotic 
effects (Figure  3B,C). qRT-PCR revealed an upregulated 
expression of the IPF-related marker genes MMP7, MMP10, 
and BPIFB1 and significantly increased MMP-7 and MMP-
10 protein levels were detected in the culture medium of day 
49 cultures stimulated with IPF-RC by ELISA, while the 
expression of CDH1, ACTA2, and COL1A1 was not altered 
(Figures 3D and S5).
RNA-seq was performed to further investigate IPF-RC 
mediated transcriptional changes (Figure  3E). In accordance 
with an upregulation of MMP-7 and MMP-10 secretion, gene 
set enrichment analysis revealed a significant enrichment of 
F I G U R E  1  Transcriptional changes characteristic of distal lung development induced during directed differentiation of human iPSCs. A, 
iPSC (line SFC065-03-03) to ATII-like cell differentiation protocol. RI = Y-27632; ActA = Activin A; SB = SB431542; Nog = Noggin; RA = all-
trans retinoic acid; CHIR = CHIR99021; DCI = dexamethasone, 8-Br-cAMP, IBMX. B, Transcription factor gene expression from day 0 to day 
24 of differentiation normalized to GAPDH relative to day 0. Mean fold change ±SD. N = 3. C, Immunofluorescence of day 24 lung progenitors 
stained against NKX2.1, FOXA2, and SOX9. Nuclei stained with Hoechst 33342. Scale bar 50 µm. D, Flow cytometry analysis of NKX2.1+ cells 
on day 24. Mean percentage of NKX2.1+ cells (±SD) is indicated. N = 3. E, ATII marker gene expression from day 24 to day 49 of differentiation 
normalized to GAPDH relative to day 0. ALI = start of air-liquid interface. Mean fold change ±SD. N = 3. F, Heatmap of top deregulated genes in 
day 49 vs day 24 cultures by RNA-seq (cutoff: q-val < 0.001, |logFC|> 2, maxRPKM > 10) with known ATII marker genes labelled on the right. 
Day 0 = iPSCs. Day 24 = lung epithelial progenitors. Day 49 = ATII-like cells
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transcripts associated with extracellular matrix organization 
(among top 10 associated gene sets under investigation; C2.CP.
REACTOME (Curated)) for the day 49 +IPF-RC phenotype 
(Figure 3F). We also compared the expression data from our 
iPSC-derived model to a publicly available data set for human 
IPF and healthy lung tissue.50 Calculation of the intersection of 
these data sets revealed a significant overlap of both downreg-
ulated (P = 4.32 × 10−16) and upregulated (P = 2.5 × 10−29) 
transcripts between day 49 cultures treated with IPF-RC and 
human IPF lungs (Figure 3G). Epithelial cell adhesion related 
transcripts (GJB1, TJP2, PCDH1, and OCLN), as well as tran-
scripts that are known to be repressed in IPF, including KLF4, 
VEGFA, IL32, and SLC19A3, were among the downregulated 
genes, while MMP10 and the airway epithelial associated tran-
scripts BPIFB1, SOX2, PAX9, TP63, FOXJ1, SCGB1A1, and 
KRT5, were upregulated in both data sets. ChIP Enrichment 
Analysis (ChEA) of deregulated genes was performed to inves-
tigate, which transcription factors could be potential upstream 
F I G U R E  2  ATII-like phenotype of 
iPSC-derived air-liquid interface (ALI) 
cultures. A, Alveolar epithelial marker gene 
expression on day 49 of differentiation 
normalized to GAPDH relative to day 0. 
Day 49 sub. = submerged conditions. Day 
49 = ALI from day 32 of differentiation 
onward. Hum. lung = total human lung 
control. Mean fold change ±SD. N = 3. ns 
not significant, ****P < .0001 by Mann-
Whitney U-test. B, Immunofluorescence 
of day 49 cultures stained against SFTPC, 
SFTPB, ABCA3, or E-Cadherin. Nuclei 
stained with DAPI. Scale bars 50 µm. C, 
Immunofluorescence of a day 49 ALI 
culture cross-section stained against SFTPC. 
Nuclei stained with DAPI. Dashed line 
indicates PET membrane of transwell insert. 
Scale bar 50 µm. D, Lamellar body-like 
structures in day 49 cultures identified by 
transmission electron microscopy. Scale 
bars in µm. E, LysoTracker Green live-
staining of iPSC-derived ATII-like cell. 
Nucleus stained with Hoechst 33342. Scale 
bar 10 µm
(A)
(B)
(C)
(E)
(D)
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drivers of the transcriptomic changes in IPF-RC treated iP-
SC-derived day 49 cultures (Figure S6). Interestingly, SOX2, a 
transcription factor known to be expressed in atypically differ-
entiated epithelial cells of bronchiolized regions in IPF lungs, 
was identified as a putative regulator of the transcriptomic sig-
nature associated with IPF-RC treatment. These results indicate 
that IPF-RC stimulation of our iPSC-derived ALI model sys-
tem allows for the recapitulation of IPF-relevant processes and 
transcriptional changes, in vitro.
3.3 | IPF-RC stimulation induces a 
shift in iPSC-derived distal lung epithelial 
progenitor cell differentiation toward a 
proximalized phenotype
As RNA-seq revealed that known airway epithelial related 
transcripts were among the upregulated transcripts upon 
IPF-RC stimulation, we sought to determine if treatment 
with IPF-RC had the potential to alter the proximo-distal 
F I G U R E  3  Fibrosis-related changes in transcriptional and secretory state caused by differentiation of iPSC-derived lung epithelial 
progenitors in the presence of an IPF-relevant cytokine cocktail (IPF-RC). A, IPF-RC stimulation during alveolar epithelial differentiation (day 
35-day 49). B, Total cell number per transwell insert. Day 49 = iPSC-derived ATII-like cells (control). Day 49 +IPF-RC = iPSC-derived cells 
treated with IPF-RC from day 35 of differentiation onward. Mean ± SD. N = 4. ns not significant by Mann-Whitney U-test. C, Caspase-3/7 
activity. Mean ± SD. N = 3. ns not significant by Mann-Whitney U-test. D, MMP-7 and MMP-10 protein levels in culture medium measured by 
ELISA. Mean ± SD. N = 3. *P < .05, **P < .01 by Mann-Whitney U-test. E, Principal component analysis of RNA-seq data representing the top 
5000 transcripts according to the coefficient of variation. Arrows represent experimental timecourse. F, Enrichment plot for the extracellular matrix 
organization gene set from Reactome. FDR q-value = 0.039. G, Intersection between deregulated transcripts in IPF-RC treated iPSC-derived day 
49 cultures (vs untreated) and deregulated transcripts in human IPF lung tissue (vs healthy). Cutoff: q-val < 0.05, |logFC| > 0.5, maxRPKM > 2. 
Top section represents downregulated, bottom section upregulated transcripts. Boxes contain examples of commonly upregulated or downregulated 
transcripts
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differentiation pattern of iPSC-derived lung epithelial pro-
genitors. Elevated expression of the transcription factor 
SOX2 and reduced expression of SOX9 were observed upon 
IPF-RC stimulation, both of which are central players in 
proximo-distal epithelial patterning during lung development 
(Figure 4A). IPF-RC treated cultures displayed significantly 
reduced expression of ATII-specific SFTPC, while the air-
way related transcripts SCGB1A1, MUC5B, FOXJ1, KRT5, 
and TP63, which are also expressed in the abnormal epi-
thelium lining cystic lesions found in distal IPF lungs, were 
significantly upregulated (Figure  4B). MUC5AC remained 
unchanged upon IPF-RC treatment, indicating that goblet cell 
associated mucin induction was specific to MUC5B, similar 
to the bronchiolized epithelium in IPF patients. Expression of 
CAV1 and PDPN was not altered, indicating that differentia-
tion of ATII-like cells toward ATI-like cells did not contrib-
ute to the loss of SFTPC expression.
To understand the relative contribution of mediators within 
the IPF-RC, individual components were removed from the 
cocktail. We focused in particular on the influence of IL-13, 
TGF-β1, and TNF-α due to their known ability to induce 
epithelial remodeling. Day 49 cultures differentiated in the 
presence of IPF-RC without IL-13 expressed higher levels of 
SFTPC than cells treated with the full cytokine cocktail, and 
F I G U R E  4  IPF-RC-induced distal-
to-proximal shift in gene expression of 
iPSC-derived lung epithelial cultures. A, 
SOX2 and SOX9 expression from day 24 
to day 49 of differentiation normalized 
to GAPDH relative to day 0. ALI = start 
of air-liquid interface. ±IPF-RC = start 
of IPF-RC/vehicle treatment. Mean fold 
change ±SD. N = 3. B, Alveolar and airway 
epithelial marker expression in day 49 
cultures ±IPF-RC treatment normalized to 
GAPDH relative to day 0. Mean fold change 
±SD. N = 9. ns not significant, *P < .05, 
**P < .01, ***P < .001 and ****P < .0001 
by two-tailed Student's t test
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displayed lower expression of MMP10, BPIFB1, MUC5B, 
FOXJ1, and TP63, suggesting IL-13 as the predominant driver 
of the IPF-related effects exerted by IPF-RC (Figure S7A). 
However, removal of IL-13 did not reduce the expression of 
MMP7, SCGB1A1, and KRT5 compared to the full cocktail. 
Furthermore, stimulation with 2.5 ng/mL of IL-13 alone re-
sulted in a significant downregulation of SFTPC expression 
and upregulation of FOXJ1 and TP63 expression, but did not 
alter the expression of MMP10, BPIFB1, or MUC5B, indi-
cating that IL-13 was not solely responsible for the proxi-
malization effect of IPF-RC (Figure S7B). IPF-RC without 
TGF-β1 led to a reduction in MUC5B expression compared 
to the full cocktail, yet failed to reduce IPF-RC mediated ex-
pressional changes in any of the other transcripts analyzed 
(Figure S7A). Removal of TNF-α did not result in a reduced 
induction of any IPF- or airway-associated transcripts com-
pared to IPF-RC (Figure S7A). Moreover, TGF-β1 or TNF-α 
removal failed to rescue SFTPC expression. These results 
indicate that TGF-β1 and TNF-α were not the main drivers 
of the bronchiolization-like effect cause by IPF-RC in our 
model system. The individual removal of the other six cy-
tokines (IL-1β, IL-8, MCP1, IL-33, TSLP, and IL-4) from 
the IPF-RC did not induce any significant alterations in the 
expression of IPF-related transcripts (MMP10, BPIFB1), 
of airway related transcripts, including MUC5B and TP63, 
nor of ATII-specific SFTPC compared to the full cocktail 
(Figure S8). These findings suggest that no individual cyto-
kine was the sole driver of the effect of IPF-RC on iPSC-de-
rived epithelial cultures.
Nintedanib, a tyrosine kinase inhibitor known to slow 
down IPF-related lung function decline, only showed some 
minor effects on SCGB1A1 and TP63 expression at clinically 
relevant concentrations (100 nM), but was neither able to res-
cue induction of IPF- and other airway-related marker genes, 
nor the reduction in SFTPC expression in IPF-RC treated 
cells (Figure S9).
In accordance with the reduced SFTPC expression in 
IPF-RC cultures, the mean surface area covered by SFTPC+ 
cells was significantly reduced in day 49 IPF-RC cultures 
compared to controls, indicating a loss of ATII-like cells 
(Figure 5A,B). Histological analysis of cross-sectioned day 
49 cultures revealed that IPF-RC stimulation resulted in the 
emergence of Alcian Blue/PAS+ cell clusters, displaying 
a secretory cell-like morphology (Figure  5C). Moreover, 
areas of MUC5B+ goblet-like cells, which were absent in 
controls, were detected in IPF-RC cultures by immunoflu-
orescence (Figure 5D). These results show that IPF-RC led 
to the emergence of MUC5B+ secretory cells, which are 
also frequently observed lining cystic lesions in the dis-
tal lung of IPF patients, at the expense of ATII-like cell 
differentiation.
3.4 | IPF-RC treatment during primary 
small airway basal cell differentiation favors 
MUC5AC+ goblet cell and impairs ciliary 
cell formation
As airway basal cells have been proposed as a source of 
the bronchiolized distal lung epithelium in IPF, we also as-
sessed the effect of IPF-RC treatment on primary small 
airway basal cell differentiation at ALI. Similar to our iPSC-
derived cultures, IPF-RC stimulation-induced upregulated 
expression of KRT5, TP63, MMP7, MMP10, and BPIFB1, 
as well as increased secretion of MMP-7 and MMP-10 in 
small SAEC cultures (Figure  6A-C). Conversely, expres-
sion of SCGB1A1 and FOXJ1 decreased compared to con-
trol cultures and MUC5AC expression was enhanced, while 
no significant deregulation of MUC5B expression could be 
detected, the upregulation of which has been linked to epi-
thelial dysfunction in IPF. TEER and dextran permeability 
measurements revealed that IPF-RC treatment resulted in a 
reduction of epithelial barrier integrity in SAEC ALI cultures 
(Figure S10). Cilia formation and ciliary function were also 
severely impaired in IPF-RC treated small airway epithelium 
(Figure 6D). These results indicate that the effect of IPF-RC 
on primary small airway basal cell differentiation differs 
from its effect on iPSC-derived alveolar epithelial progenitor 
cell differentiation.
We further examined the effect of IPF-RC stimulation on 
primary human small airway basal cell proliferation in sub-
merged culture (Figure S11). No significant difference was 
detected between treated cultures and vehicle controls, sug-
gesting that IPF-RC does not induce a proliferative expansion 
of airway basal cells.
3.5 | The metaplastic epithelium lining 
cystic lesions in IPF lungs contains atypical 
transition zones between SFTPC+ ATII-like 
cells and MUC5B+ goblet-like cells
To confirm the relevance of the findings observed in our 
model system for human disease, immunofluorescence in 
IPF patient lung sections was performed. The heterogene-
ous cystic lesions found in the dense fibrotic tissue of the 
distal IPF lungs were lined by a simple single-layered co-
lumnar or cuboidal epithelium, interrupted by areas of epi-
thelial denudation and areas of multi-layered hyperplastic 
epithelium. Double immunofluorescence against SFTPC 
and MUC5B was performed in three IPF lungs. In accord-
ance with previous reports that identified MUC5B+ secretory 
cells as the predominant mucus cell type in the honeycomb 
epithelium, many of the cystic lesions found in the distal 
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regions of IPF lungs were lined by MUC5B expressing co-
lumnar epithelial cells and displayed extensive mucus plug-
ging. Immunofluorescence further confirmed the presence of 
SFTPC+ cells in distal IPF patients’ lungs, with some cystic 
lesions lined exclusively by a simple SFTPC+ epithelial cell 
layer, indicative of ATII cell hyperplasia (Figure  7). The 
luminal space of some lesions contained yellow appearing 
material, indicative of a mixture of mucus and surfactant se-
cretions. Interestingly, we also detected cystic lesions that 
were lined by a metaplastic epithelium characterized by an 
atypical transition from a SFTPC+ epithelium to a MUC5B+ 
epithelium in all analyzed IPF samples (Figure  7). These 
transition zones of ATII-like cells residing in close proximity 
to goblet-like cells are indicative of a loss of regional epi-
thelial specification and could represent areas of progressing 
alveolar bronchiolization.
4 |  DISCUSSION
In this study, we establish a novel iPSC-derived ALI model 
of alveolar epithelial differentiation to investigate epithe-
lial dysfunction related to IPF. Utilizing this system, we 
demonstrate how an IPF-relevant cytokine environment can 
skew iPSC-derived ATII-like differentiation toward proxi-
mal lineages and induce disease-related changes, including 
secretion of IPF biomarkers. This report thereby describes, 
for the first time, a human model system that recapitulates 
key aspects of IPF-related bronchiolization in vitro.
While ALI culture has been applied to human pluripotent 
stem cell (hPSC)-derived airway epithelial cells to enhance 
maturation, this method has not yet been tested in hPSC-de-
rived models of the alveolar epithelium.55,56 We show for the 
first time, the maturation of hPSC-derived lung epithelial 
progenitor cells toward ATII-like cells in an ALI culture for-
mat, providing a novel platform for both basic research and 
drug discovery purposes. Our data show that iPSC-derived 
lung epithelial progenitor cells differentiated at ALI express 
higher levels of SFTPC, SFTPB, and ABCA3 compared to 
submerged controls. Importantly, SFTPC+ cells are located 
on the apical surface of the airlifted cultures, suggestive of a 
positive influence of air exposure on ATII-like differentiation. 
Interestingly, ABCA3 positive cells, which are not detect-
able in human fetal lungs prior to 22-23 weeks of gestation, 
are present within our system.57 The cultures also express 
TM4SF1 which has been described as a marker for alveolar 
F I G U R E  5  Epithelial phenotypic 
changes recapitulating aspects of IPF-related 
bronchiolization resulting from IPF-RC 
stimulation during iPSC-derived lung 
epithelial progenitor cell differentiation. A, 
Immunofluorescence against SFTPC in day 
49 cultures ±IPF-RC. Nuclei stained with 
DAPI. Scale bars 50 µm. B, SFTPC+ surface 
area quantified by immunofluorescence. 
Mean SFTPC+ area per image ±SD. N = 3 
independent differentiation rounds. (n = 3 
biological replicates per differentiation 
round and nine images per replicate). 
*P < .05 by Mann-Whitney U-test. C, H&E 
and Alcian Blue/PAS stain of iPSC-derived 
culture cross-sections. Scale bars 50 µm. D, 
Immunofluorescence against MUC5B in day 
49 cultures ±IPF-RC. Nuclei stained with 
DAPI. Scale bars 40 µm
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epithelial progenitor cells within the adult human lung.16 In 
addition, lamellar bodies, ATII specific surfactant producing/
storing organelles, are present in the cultures.28,58-60 Taken 
together, these results confirm the feasibility of ATII-like cell 
derivation from iPSC-derived lung progenitor cells in ALI 
culture.
F I G U R E  6  IPF-RC-induced alterations in primary human small airway epithelial cell (SAEC) differentiation. A, Gene expression in primary 
human SAEC cultures normalized to GAPDH relative to untreated controls. Day 28 = SAECs differentiated for 28 days at air-liquid interface 
culture. Day 28 +IPF-RC = SAECs differentiated for 28 days at air-liquid interface in the presence of IPF-RC. Mean fold change ±SD. N = 3. 
ns not significant, **P < .01, ***P < .001, and ****P < .0001 by Mann-Whitney U-test. B, Representative H&E (left), Alcian Blue/PAS stain 
(middle), and immunofluorescence double stain (right) of primary human SAEC cultures. Immunofluorescence against MUC5AC (green) and 
KRT5 (red). Nuclei stained with DAPI (blue). Scale bars 50 µm. C, MMP-7 and MMP-10 protein levels in cell culture supernatant of SAEC 
cultures. Mean ± SD. N = 3. **P < .01, and ****P < .0001 by Mann-Whitney U-test. D, Ciliary beat measurement in SAEC cultures. Mean 
area covered by motile cilia and mean ciliary beat frequency calculated from N = 3 independent experiments. About 6 regions per insert from 3 
biological replicates analyzed per experiment. Error bars represent SD. ****P < .0001 by Mann-Whitney U-test. Representative regions analyzed 
for cilia beat measurement shown on the right
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The disease-specific milieu within the lung has been sug-
gested to play a central role in the pathogenesis of IPF.61,62 
While there is substantial evidence for the relevance of var-
ious cytokines and growth factors in IPF, including TGF-β, 
TGF-α, IL-13, TNF-α and IL-1β, the overexpression of which 
induces pulmonary fibrosis in animal models, no single fac-
tor is known to simultaneously activate all IPF-related path-
ways.63,64 Despite this fact, many currently available in vitro 
models of pulmonary fibrosis rely on a single stimulus.65 
To mimic a pro-fibrotic milieu in vitro, we designed a novel 
cocktail (IPF-RC) containing nine IPF-relevant cytokines 
and assessed its effect on differentiating iPSC-derived distal 
lung epithelial progenitor cells.35-43 As we primarily aimed 
to investigate the effect of a fibrosis-relevant environment on 
progenitors of the alveolar epithelium, IPF-RC stimulation 
was initiated by day 35 of the protocol, following induction 
of SFTPC expression, which constitutes a specific feature of 
alveolar epithelial progenitors in fetal human lungs.66-68
Analysis of the culture medium in IPF-RC treated cells 
showed increased MMP-7 and MMP-10, both of which are el-
evated in IPF patient BAL and serum, and RNA-seq analysis 
revealed an enrichment of transcripts involved in extracellular 
matrix organization, indicating an induction of IPF-relevant 
processes.69-71 Furthermore, a comparison of transcriptional 
changes in IPF-RC treated iPSC-derived cultures and human 
IPF patient lungs revealed a significant overlap of upregu-
lated and downregulated transcripts.50 On the content, there 
is also a substantial amount of nonoverlapping deregulated 
genes, likely both due to the heterogeneity of our culture 
system and the origin of the publicly available IPF patient 
data set. The analysis of whole human lung homogenates 
contains multiple cell types (eg, mesenchymal, endothelial, 
and immune cells) that are not represented in our in vitro 
model system. This is supported by the presence of known 
epithelial-specific transcripts among the commonly deregu-
lated genes, many of which have been associated with lung 
F I G U R E  7  Epithelial transition 
zones in cystic lesions of IPF patient lungs. 
Representative hematoxylin and eosin stain 
(H&E) and immunofluorescence against 
SFTPC (green) and MUC5B (red) in N = 3 
human IPF lungs. Epithelial transition zones 
in cystic lesions lined by SFTPC+ cells 
(filled arrow heads) and MUC5B+ cells 
(unfilled arrow heads). Nuclei stained with 
DAPI (blue). Scale bars 350 µm in H&E 
images; 50 µm in immunofluorescence 
images
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fibrosis. In accordance with previous reports, KLF4, VEGFA, 
IL32, and SLC19A3 are among the commonly downregulated 
transcripts.7,72-74 BPIFB1 which was described to localize to 
the bronchiolized epithelium in the honeycomb cysts in usual 
interstitial pneumonia and MMP10, are among the commonly 
upregulated transcripts.75,76 Taken together, our iPSC-de-
rived in vitro model mimics certain IPF-related changes in 
epithelial transcription and secretory phenotype.
In addition, RNA-seq data reveal many known airway as-
sociated transcripts with known roles in the developing and 
adult proximal lung, were among the top upregulated tran-
scripts in IPF-RC treated iPSC-derived cultures, for example, 
SOX2, PAX9, TP63, KRT5, FOXJ1, SCGB1A1, and MUC5B, 
which have recently been confirmed as markers for the al-
tered IPF lung epithelium via single-cell sequencing.5,7,9,76-78 
Upregulation of airway marker expression following IPF-RC 
stimulation is accompanied by a loss of ATII specific SFTPC 
expression and a shift in the expression of SOX2 and SOX9, 
two transcription factors known as central players in prox-
imo-distal epithelial patterning during human and mouse 
lung development.28,67 Mouse studies have revealed an es-
sential role of Sox9 during branching morphogenesis, cor-
rect distal lung epithelial differentiation during development, 
as well as recovery of lung function after acute lung injury 
in adult mice.79,80 Expression of SOX2, which is associated 
with proximal airway rather than alveolar identity in healthy 
lungs, has been shown in the bronchiolized and enlarged dis-
tal airspaces in IPF.5 Moreover, two murine studies have in-
dependently shown that selective overexpression of Sox2 in 
adult ATII cells resulted in an induction of conducting airway 
related transcript expression in the alveoli.81,82 In our study, 
SOX2 was identified as a putative regulator of the transcrip-
tomic signature associated with IPF-RC treatment by ChIP 
enrichment analysis (ChEA). Based on previous observations 
described in the literature and the findings from this study, 
we hypothesize that SOX2 activation in IPF could promote 
the bronchiolization-like effect induced by a fibrosis-related 
cytokine milieu.
Immunohistological analysis of iPSC-derived cultures dif-
ferentiated in the presence of IPF-RC revealed a significant 
reduction in SFTPC+ cell area and the emergence MUC5B+ 
secretory-like cells, an important role of which has been 
suggested in IPF. Not only has it been shown that MUC5B+ 
cells abundantly reside within the bronchiolized IPF epithe-
lium, but also a MUC5B promoter polymorphism, known to 
enhance MUC5B expression in the bronchiolo-alveolar epi-
thelia, constitutes the strongest currently known genetic risk 
factor for IPF.5,6,83,84 We further demonstrated in this study, 
that highly aberrant direct transition zones between SFTPC+ 
and MUC5B+ epithelium exist within distal IPF patient lungs. 
Based on our findings in a human iPSC-derived alveolar epi-
thelial model and IPF patient lungs, we hypothesize that alve-
olar epithelial progenitor cells could contribute to epithelial 
bronchiolization of the distal compartments of the IPF lung 
via aberrant trans-differentiation toward airway-like lineages.
In our model system, removal of IL-13, but not of any 
other individual cytokine, from IPF-RC impairs its ability to 
promote differentiation toward airway-like cell fates at the 
cost of ATII-like cell differentiation, indicating IL-13 as one 
of the main drivers of the proximalization effect we observed 
following IPF-RC stimulation. IL-13 has been described 
as a main mediator in respiratory diseases, particularly in 
asthma, where it is linked to mucus secretion and fibrogenic 
processes.85 Moreover, IL-13 overexpression leads to pulmo-
nary fibrosis in mice and it has been hypothesized that IL-13 
antagonism could constitute a potential treatment strategy for 
IPF.86 While IL-13 alone is sufficient to repress SFTPC ex-
pression, in line with the previous findings in primary human 
ATII cells,87 it fails to fully recapitulate the influence of the 
IPF-RC on airway-specific and IPF-relevant transcripts. Our 
results are in accordance with the current consensus that 
neither IL-13, nor any other single factor is sufficient to si-
multaneously activate all IPF-related pathways in vitro and 
highlight the importance of more physiological human in 
vitro model systems.64 This is underlined by the recent fail-
ure of the phase 2 clinical study of tralokinumab, a human 
anti-IL-13 monoclonal antibody, in subjects with IPF.88
It has been proposed that migrating airway stem cells, 
rather than resident alveolar stem cells, are the stem cell 
source of the bronchiolized epithelium. As our model sys-
tem contains rare individual KRT5+ basal-like cells, their 
role in the IPF-RC mediated effects cannot be excluded. 
However, as IPF-RC treatment of small airway basal 
cells induced a strong upregulation of MUC5AC, but not 
MUC5B, contrary to the abundant emergence of aberrant 
MUC5B+ cells in the bronchiolized distal airspaces in 
IPF patients, as well as suppressed the expression of tran-
scripts upregulated in the IPF lung such as SCGB1A1 and 
FOXJ1, the airway-like phenotype observed in iPSC-de-
rived IPF-RC cultures is unlikely the sole result of bas-
al-like cell expansion and differentiation.5,6,76,77 Moreover, 
IPF-RC stimulation did not induce proliferation of primary 
small airway basal cells compared to controls. In the future, 
lineage tracing of SFTPC+ ATII-like cells and KRT5+ bas-
al-like cells should be performed in order to conclusively 
determine the definite origin of the bronchial-like cells in 
our iPSC-derived model system.
The usual interstitial pneumonia pattern in IPF is character-
ized by high temporal and spatial heterogeneity.89 We hypoth-
esize that our in vitro system utilizing an IPF-relevant cytokine 
cocktail, could potentially model the progression of epithelial 
dysfunction from severely affected toward healthy neighboring 
regions of the lung via a distribution of the pro-fibrotic milieu 
produced in diseased fibrotic areas within the lung and expo-
sure of epithelial progenitor cells in previously unaffected re-
gions to this milieu. However, as the definite composition of 
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the IPF BAL/lung milieu is not known, the combination of nine 
cytokines cannot fully mimic the environment epithelial cells 
are exposed to in a diseased lung. Moreover, the model utilized 
in this study does not encapsulate the complex cellular interplay 
that leads to the vicious cycle of wound repair and scar forma-
tion that occurs in IPF,90 nor the role of genetic risk factors in 
IPF pathogenesis.18 In the future, one could envision utilizing 
this model in coculture with other structural (fibroblasts, endo-
thelial cells) and immune cells, or on the background of preex-
isting epithelial damage (eg, mechanical wounding) to better 
understand the role of a pro-fibrotic extracellular milieu in a 
more physiologically relevant setting.
Overall, our findings highlight that the fibrosis-related 
milieu present in the IPF lung has the potential to skew alve-
olar epithelial differentiation toward airway cell phenotypes. 
Our data suggest that aberrant trans-differentiation of epithe-
lial stem cells in the fibrotic lung could disrupt the regular 
proximo-distal patterning of the lung epithelium and thereby 
contribute to the emergence of aberrant epithelial cell types, 
as well as the apparent bronchiolization in the distal IPF lung. 
This raises the need for further investigations to determine 
the exact pathophysiological mechanisms underlying alveo-
lar epithelial cell dysfunction in IPF, which may open routes 
to novel therapeutic concepts not yet covered by current stan-
dard of care therapies.
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